Table 1.
Baseline clinical attributes of the study sample.
| GWAS cohort | Resequencing cohort | |||
|---|---|---|---|---|
| | ||||
| HTG | Controls | HTG | Controls | |
| Number | 463 | 1197 | 438 | 327 |
| Female | 30.7% | 40.4% | 33.2% | 50.5% |
| Diabetes | 25.7% | 0.4% | 28.1% | 4.1% |
| Age (years) | 50.9 ± 13.0 | 47.8 ± 11.1 | 51.3 ± 13.1 | 49.9 ± 15.1 |
| Body mass index (kg/m2) | 29.9 ± 4.9 | 26.4 ± 4.6 | 30.0 ± 4.9 | 26.8 ± 4.5 |
| Plasma total cholesterol (mmol/L) | 8.2 ± 3.9 | 5.3 ± 1.3 | 8.7 ± 4.3 | 4.9 ± 0.8 |
| Plasma HDL cholesterol (mmol/L) | 0.9 ± 0.3 | 1.4 ± 0.4 | 0.9 ± 0.3 | 1.3 ± 0.4 |
| Plasma LDL cholesterol (mmol/L) | - | 3.4 ± 1.2 | - | 3.2 ± 0.9 |
| Plasma triglycerides (mmol/L) | 14.3 ± 19.8 | 1.1 ± 0.7 | 14.2 ± 19.0 | 1.2 ± 0.4 |
GWAS, genome-wide association study; HDL, high-density lipoprotein; HTG, hypertriglyceridemia; LDL, low-density lipoprotein. There are 346 HTG patients and 205 low triglyceride controls common between both cohorts. Lipid measurements were conducted after a 12-h fasting period. Values are mean ± standard deviation. LDL cholesterol is not accurately calculated using the Friedewald equation for HTG patients when plasma triglyceride concentration exceeds 4.5 mmol/L.